World Stroke Congress | TASTE-2 significantly reduces stroke disability
NANJING, China, Oct. 30, 2024 /PRNewswire/ -- Oct 24th 2024, Simcere Pharmaceuticals Group Ltd. (2096.HK) announced that a new clinical study with major clinical findings regarding Sanbexin (edaravone and dexborneol concentrated solution for injection) has been published at the 16th World Stroke...
TASTE-2 World Stroke Congress | Sanbexin ® combined with thrombectomy significantly reduces stroke disability
NANJING, China, Oct. 25, 2024 /PRNewswire/ -- On October 24, 2024, TASTE-2, a Chinese innovative stroke drug study led by Professor Wang Yongjun from Beijing Tiantan Hospital, was published in an oral report at the 16th World Stroke Conference (WSC): brain cell protection combined with edaravone ...
Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration
NANJING, China, Sept. 14, 2024 /PRNewswire/ -- On September 2, 2024, Simcere Pharmaceuticals Group Ltd. (2096.HK) announced that Sanbexin Sublingual Tablets (Edaravone and Dexborneol sublingual tablets), an innovative drug for stroke, has been granted the Breakthrough Therapy designation by the U...
Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration
NANJING, China, Sept. 5, 2024 /PRNewswire/ -- On September 2, 2024, Simcere Pharmaceuticals Group Ltd. (2096.HK) announced that Sanbexin Sublingual Tablets (Edaravone and Dexborneol sublingual tablets), an innovative drug for stroke, has been granted the Breakthrough Therapy designation by the U....
Simcere Zaiming collaborates with TargetRx to introduce a third-generation ALK inhibitor
NANJING, China, Sept. 2, 2024 /PRNewswire/ -- On September 02, 2024, Simcere Zaiming, an innovative oncology company under Simcere Pharmaceutical Group (2096.HK), announced a collaboration agreement with Shenzhen TargetRx Inc. The partnership focuses on the ALK/ROS1 dual receptor tyrosine kinase ...
Simcere Zaiming Announce Approval of Cetuximab Beta in China by the NMPA
NANJING, China, June 26, 2024 /PRNewswire/ -- On June 25, 2024, Simcere Zaiming, an innovative oncology company and a subsidiary of Simcere Pharmaceutical Group (2096.HK), announced that Enlituo® (generic name: cetuximab beta injection), a new generation anti-epidermal growth factor receptor (EG...
Simcere and Connect Enter into an exclusive license and collaboration agreement for the innovative autoimmune drug Rademikibart
NANJING, China, Nov. 23, 2023 /PRNewswire/ -- On November 21, 2023, Simcere Pharmaceutical Group Limited ("Simcere") entered into an exclusive license and collaboration agreement (the "Agreement") with Connect Biopharma HongKong Limited ("Connect") in relation to Rademikibart, an innovative IL...
Four innovative drugs launched in three years, HKEX -Listed Simcere Pharmaceutical Group is on the Fast Track Toward Building an Innovation-Driven Global Pharmaceutical Company
-The revenue from innovative drugs accounted for more than 65% of total revenue -Simcere's total revenue and the revenue from innovative drugs hit record highs. NANJING, China, April 24, 2023 /PRNewswire/ -- On Apr. 18, Simcere Pharmaceutical (2096.HK) disclosed the latest progress on the compa...
Simcere Zaiming Announces Clinical Collaboration to Evaluate SIM0235, a TNFR2 Monoclonal Antibody, in Combination with KEYTRUDA® (pembrolizumab) in a Phase 1 Trial in Advanced Solid Tumors and Cutaneous T-cell Lymphoma
NANJING, China, March 14, 2023 /PRNewswire/ -- Simcere Pharmaceutical Group Limited (2096.HK) (Simcere), an innovative global biopharmaceutical company, announced today that Simcere Zaiming, an innovative oncology pharmaceutical company of Simcere has entered into a clinical collaboration agreeme...
First Prescription for COSELA® (trilaciclib) Issued in China
- COSELA®, the world's first and only myeloprotection drug, was prescribed in Jilin Cancer Hospital onJanuary 28, 2023 - Simcere delivers drug to patients in 908 days from execution of license agreement to first prescription NANJING, China, Feb. 9, 2023 /PRNewswire/ -- Simcere Pharmaceutical Gr...
PHASE II/III CLINICAL TRIAL OF SIMCERE'S 3CL-TARGETING ANTI-SARS-COV-2 DRUG CANDIDATE COMPLETE ALL PATIENTS ENROLLMENT
NANJING, China, Dec. 20, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group (2096.HK) announced today that, XIANNUOXIN (SIM0417), an anti-SARS-CoV-2 drug candidate jointly developed by Simcere with Shanghai Institute ofMateria Medica (the "SIMM") and Wuhan Institute of Virology (the "WIV"), Chines...
Simcere and Idorsia enter into a licensing agreement for daridorexant in China
NANJING, China, Nov. 15, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group Ltd (2096.HK, "Simcere"), an innovation and R&D-driven pharmaceutical company,and Idorsia Ltd (SIX: IDIA, "Idorsia"), specialized in the discovery, development and commercialization of small molecules to transform the hori...
Simcere Receives FDA Clearance of Investigational New Drug Application (IND) for Bi-functional Fusion Protein, SIM0237
Second US IND approval this year for the global pharmaceutical group NANJING, China and BOSTON, Oct. 27, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group (2096.HK), an innovative global pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the com...
Simcere and Almirall Enter into a Licensing Agreement for IL-2 mu-Fc
* Simcere will receive a $15 million upfront payment, and up to $492 million in development and commercial milestone payments considering successful achievements in several indications, with an important part as sales milestones, as well as up to low double-digit tiered royalties based upon fu...
Simcere Pharmaceutical Announces Financial Results for 2022 H1: 27% Year-Over-Year Revenue Growth, with Innovative Drugs Accounting for 65.4% of Total Revenue
NANJING, China, Sept. 5, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group Limited (2096.HK) announced its financial results for the first half of 2022. As ofJune 30, Simcere recorded operating revenue of RMB 2.7 billion for the first half of the year, with a year-over-year growth of 27.3%. The e...
Tamas Oravecz Ph.D. named SVP, CSO of the U.S. of Simcere Pharmaceutical Group
NANJING, China, Sept. 5, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group announces today the appointment ofTamas Oravecz, Ph.D. as Senior Vice President, Chief Scientific Officer of the Simcere U.S. Tamas will be responsible for providing strategic leadership to our drug discovery efforts in A...
SIMCERE PHARMA (HK.2096) Novel Inhibitor of COVID-19 3CLpro SIM0417 Received a Second Clinical Trial Approval in China
HONG KONG, May 18, 2022 /PRNewswire/ -- SIMCERE PHARMA (HK.2096) announced that SIM0417, a candidate drug against SARS-Cov-2, for which the Company holds license from Shanghai Institute ofMateria Medica (SIMM) and Wuhan Institute of Virology, Chinese Academy of Sciences, has obtained the Clinica...
Proprietary SARS-CoV-2 3CL Inhibitor Rapidly Progressing in Clinical Trials, Market Approval of Trilaciclib Expected in China, Simcere Reveals Global Innovation Ambition on R&D Day
NANJING, China, April 19, 2022 /PRNewswire/ -- On April 15, 2022, Simcere Pharmaceutical (2096.HK), an innovation and R&D driven pharmaceutical company in China held its first R&D day for international investors, during which the executive leaders revealed Simere's R&D strategy, and gave an update...
SIMCERE PHARMA (HK.2096) to host 2022 R&D Day
HONG KONG, April 7, 2022 /PRNewswire/ -- SIMCERE PHARMA (HK.2096), an innovation and R&D-driven pharmaceutical company with a mission of "providing today's patients with medicines of the future", will host a virtual R&D Day, on Friday,15 April, 2022, at 21:00-23:00 (HKT) / 9:00-11:00 (EST) / 13:0...
Primary endpoint met in Phase III clinical trial of Trilaciclib in Chinese patients with small cell lung cancer
HONG KONG, Feb. 24, 2022 /PRNewswire/ -- On February 23 2022, Simcere Pharmaceutical Group (2096.HK) announced that the phase III clinical registration study of Trilaciclib in patients with extensive-stage small cell lung cancer (ES-SCLC) has met its primary endpoint. The drug co-developed in Chi...
